The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Isolation of High Avidity Melanoma-Reactive CTL from Heterogeneous Populations Using Peptide-MHC Tetramers
Abstract
Immunogenic peptides of human tumor Ag have been used to generate antigen-specific CTL. However, the vast majority of these peptide-specific CTL clones are of low avidity and are peptide, but not tumor, reactive. Peptide-MHC tetramers have been shown to bind specific TCRs with sufficient affinity to be useful reagents for flow cytometry. In this paper we demonstrate that peptide-MHC tetramers can also be used to selectively identify high avidity tumor-reactive CTL and enrich, from a heterogeneous population, the subpopulation of peptide-reactive T cells that can lyse tumor targets. The melanoma proteins, MART-1 and gp100, were used to induce potentially tumor-reactive T cells, and the intensity of T cell staining by TCR binding of specific peptide-MHC tetramers was assessed. A range of fluorescence intensity was detected, and the magnitude of tetramer binding was correlated with T cell avidity. The population of peptide-reactive T cells was phenotypically similar with regard to expression of TCR and adhesion molecules, suggesting that this differential avidity for tumor cells reflected differential affinity of the TCR for its peptide-MHC ligand. Sorting, cloning, and expansion of tetramerhigh CTL from a heterogeneous population of peptide-stimulated PBMCs enabled rapid selection of high avidity tumor-reactive CTL clones, which retained their functional and tetramerhigh phenotype on re-expansion. These results demonstrate that the avidity of a T cell for its tumor target is due to the specific affinity of the TCR for its peptide-MHC ligand, that this interaction can be described using peptide-MHC tetramers and used to isolate high avidity tumor-reactive CTL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544
Self-citationRosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., & Riddell, S. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510193331603 · Cited by 1,771
Self-citationKawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3515 · Cited by 1,092
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A
Lee, N., Llano, M., Carretero, M., Ishitani, A., Navarro, F., López-Botet, M., & Geraghty, D. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5199 · Cited by 1,053
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6458 · Cited by 914
Coulie, P. G., Brichard, V, Van Pel, A., Wölfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.35 · Cited by 903
Callan, M. F. C., Tan, L., Annels, N., Ogg, G. S., Wilson, J. D. K., O'Callaghan, C. A., Steven, N., McMichael, A. J., & Rickinson, A. B. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1395 · Cited by 892
Gallimore, A., Glithero, A., Godkin, A., Tissot, A. C., Plückthun, A., Elliott, T., Hengartner, H., & Zinkernagel, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1383 · Cited by 763
Evidence for a differential avidity model of T cell selection in the thymus
Ashton-Rickardt, P. G., Bandeira, A., Delaney, J. R., Van Kaer, L., Pircher, H.-P., Zinkernagel, R. M., & Tonegawa, S. (1994) · Cell · doi:10.1016/0092-8674(94)90505-3 · Cited by 668
Cited by
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Self-citationYee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., & Greenberg, P. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242600099 · Cited by 1,206
Self-citationTranslating Stem and Progenitor Cell Biology to the Clinic: Barriers and Opportunities
Weissman, I. L. (2000) · Science · doi:10.1126/science.287.5457.1442 · Cited by 852
Maus, M. V., Thomas, A. K., Leonard, D. G. B., Allman, D., Addya, K., Schlienger, K., Riley, J. L., & June, C. H. (2002) · Nature Biotechnology · doi:10.1038/nbt0202-143 · Cited by 454
Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma
Yee, C., Thompson, J. A., Roche, P., Byrd, D. R., Lee, P. P., Piepkorn, M., Kenyon, K., Davis, M. M., Riddell, S. R., & Greenberg, P. D. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.11.1637 · Cited by 428
Self-citationEx vivo identification, isolation and analysis of tumor-cytolytic T cells
Rubio, V., Stuge, T. B., Singh, N., Betts, M. R., Weber, J. S., Roederer, M., & Lee, P. P. (2003) · Nature Medicine · doi:10.1038/nm942 · Cited by 400
Self-citationRecruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
Ercolini, A. M., Ladle, B. H., Manning, E. A., Pfannenstiel, L. W., Armstrong, T. D., Machiels, J.-P. H., Bieler, J. G., Emens, L. A., Reilly, R. T., & Jaffee, E. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042167 · Cited by 399
CD8+ T cell efficacy in vaccination and disease
Appay, V., Douek, D. C., & Price, D. A. (2008) · Nature Medicine · doi:10.1038/nm.f.1774 · Cited by 393
Molecules and mechanisms of the graft-versus-leukaemia effect
Bleakley, M., & Riddell, S. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1365 · Cited by 392
Impact of Negative Selection on the T Cell Repertoire Reactive to a Self-Peptide
Bouneaud, C., Kourilsky, P., & Bousso, P. (2000) · Immunity · doi:10.1016/s1074-7613(00)00080-7 · Cited by 391
Novak, E. J., Liu, A. W., Nepom, G. T., & Kwok, W. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8476 · Cited by 376
Design and use of conditional MHC class I ligands
Toebes, M., Coccoris, M., Bins, A., Rodenko, B., Gomez, R., Nieuwkoop, N. J., van de Kasteele, W., Rimmelzwaan, G. F., Haanen, J. B. A. G., Ovaa, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1360 · Cited by 347
Functional avidity maturation of CD8+ T cells without selection of higher affinity TCR
Slifka, M. K., & Whitton, J. L. (2001) · Nature Immunology · doi:10.1038/90650 · Cited by 344
Strategies for designing and optimizing new generation vaccines
Berzofsky, J. A., Ahlers, J. D., & Belyakov, I. M. (2001) · Nature Reviews Immunology · doi:10.1038/35105075 · Cited by 334
Engelhardt, J. J., Boldajipour, B., Beemiller, P., Pandurangi, P., Sorensen, C., Werb, Z., Egeblad, M., & Krummel, M. F. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.008 · Cited by 330
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
Mapara, M. Y., & Sykes, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.041 · Cited by 325
Oelke, M., Maus, M. V., Didiano, D., June, C. H., Mackensen, A., & Schneck, J. P. (2003) · Nature Medicine · doi:10.1038/nm869 · Cited by 306
T cell anergy and costimulation
Appleman, L. J., & Boussiotis, V. A. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00009.x · Cited by 305
Mandl, J. N., Monteiro, J. P., Vrisekoop, N., & Germain, R. N. (2013) · Immunity · doi:10.1016/j.immuni.2012.09.011 · Cited by 304
Accessing Complexity: The Dynamics of Virus-Specific T Cell Responses
Doherty, P. C., & Christensen, J. P. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.561 · Cited by 279
IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response
Li, Y., Bleakley, M., & Yee, C. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2261 · Cited by 273
Self-citationRees, W., Bender, J., Teague, T. K., Kedl, R. M., Crawford, F., Marrack, P., & Kappler, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9781 · Cited by 262
Principles of adoptive T cell cancer therapy
June, C. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31446 · Cited by 261
Ludewig, B., Ochsenbein, A. F., Odermatt, B., Paulin, D., Hengartner, H., & Zinkernagel, R. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.795 · Cited by 252
Brown, I. E., Blank, C., Kline, J., Kacha, A. K., & Gajewski, T. F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4521 · Cited by 91
Clonal lineage tracing reveals mechanisms skewing CD8+ T cell fate decisions in chronic infection
Kasmani, M. Y., Zander, R., Chung, H. K., Chen, Y., Khatun, A., Damo, M., Topchyan, P., Johnson, K. E., Levashova, D., Burns, R., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20220679 · Cited by 87
Barbon, C. M., Yang, M., Wands, G. D., Ramesh, R., Slusher, B. S., Hedley, M. L., & Luby, T. M. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.02.007 · Cited by 36
Multimer monitoring of CMV-specific T cells in research and in clinical applications
Borchers, S., Ogonek, J., Varanasi, P. R., Tischer, S., Bremm, M., Eiz-Vesper, B., Koehl, U., & Weissinger, E. M. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.11.007 · Cited by 18
Metadata
- Authors
- Yee, C., Savage, P. A., Lee, P. P., Davis, M. M., & Greenberg, P. D.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-02
- Volume
- 162
- Issue
- 4
- Pages
- 2227-2234
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1589097025
- Cited by
- 415
- References
- 37
- FWCI
- 13.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.